Orteronel Maintenance Therapy in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) Previously Treated With Novel Hormonal Agents and Non-progressive Disease After Treatment With a Taxane: A Multicentre Randomized Double-blind Placebo-controlled Phase III Trial
Status: Withdrawn prior to enrolment
Phase of Trial: Phase III
Latest Information Update: 02 Aug 2018
Price : $35 *
At a glance
- Drugs Orteronel (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 24 Jul 2018 Status changed from withdrawn prior to enrolment to suspended.
- 24 Jul 2018 Status changed from suspended to withdrawn prior to enrolment.